Overview

A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019)

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability and pharmacokinetics (PK) of MK0633 in adolescent mild-to-moderate asthma patients to permit further clinical investigation.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.